XCancer

89Zr-DFO-REGN3767 in PET Scans in People With Diffuse Large B Cell Lymphoma (DLBCL)

Description:

The main purposes of this study include: Looking at the way the body absorbs, distributes, and gets rid of 89Zr-DFO-REGN3767 Finding the best dose amount of 89Zr-DFO-REGN3767 Finding the best time for PET scanning after injection of 89Zr-DFO-REGN3767

Sponsor:

Memorial Sloan Kettering Cancer Center

Phase:

Early Phase 1

Contacts:

Neeta Pandi-Taskar, MD (PRINCIPAL_INVESTIGATOR)

Government Study Link:

NCT04566978 - Click here to see study on

ClinicalTrials.gov

REGN3767

Isotope(s):
Target(s):
  • LAG3
Ligand Class: Antibodies
Chelator: DFO
Inclusion
  • Patients must have eGFR \>50 mL/min/1.73m2.
  • A patient must be eligible for DLBCL expansion cohort 9 in study 17-421 and, in addition, meet the following criteria to be eligible for inclusion in the study:
  • Measurable disease by Lugano criteria, with at least one lesion outside of the liver
Exclusion
  • Patients who have permanently discontinued anti-cancer immune modulating therapies due to drug-related toxicity.
  • A patient must be eligible for DLBCL expansion cohort 9 in study 17-421 and, in addition, a patient who meets any of the following criteria will be excluded from the study: